Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1661-1668

  Emig, R ^a   Magener, A ^b   Ehemann, V ^a   Meyer, A ^b   Stilgenbauer, F ^c   Volkmann, M ^c   Wallwiener, D ^a   Sinn, H P ^b  

^a Frauenklinik   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Flow cytometry; Genetic alteration; Immunohistochemistry; p16; Proliferation

Indexed keywords

CYTOPLASM PROTEIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER GRADING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0031771435     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.739     Document Type: Article

References (43)

1. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
2. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C and Knapstein PG (1995) Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 57: 96-104
3. Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA and Foekens JA (1995) Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 72: 964-967
4. Borg A, Johannsson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, Olsson H and Ingvar C (1996) Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56: 2497-2500
5. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrik L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 11: 210-212
6. Charpin C, Devictor B, Andrac L, Amabile J, Bergeret D, Lavaut MN, Allasia C and Piana L (1995) p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol 26: 159-166
7. Enders GH, Koh J, Missero C, Rustgi AK and Harlow E (1996) p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 12: 1239-1245
8. Feichter GE, Müller A, Kaufmann M, Haag D, Born IA, Abel U, Klinga K, Kubli F and Goerttler K (1988) Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer. Int J Cancer 41: 823-828
9. Feichter GE, Kaufmann M, Müller A, Haag D, Eckhardt R and Goerttler K (1989) DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases. Breast Cancer Res Treat 13: 17-22
10. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M and Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
11. Friedrichs K, Gluba S, Eidtmann H and Jonat W (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647
12. Geradts J and Wilson PA (1996) High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 149: 15-20
13. Geradts J, Kratzke, RA, Niehans GA and Lincoln CE (1995) Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2 multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16(INK4A) in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55: 6006-6011
14. Goodrich DW and Lee WH (1993) Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1155: 43-61
15. Hara E, Smith R, Parry D, Tahara H, Stone S and Peters G (1996) Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-867
16. Hedley DW (1993) DNA Cytometry Consensus Conference. DNA flow cytometry and breast cancer. Breast Cancer Res Treat 28: 51-53
17. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-1530
18. Hunter T and Pines J (1994) Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79: 573-582
19. Isola J, Visakorpi T, Holli K and Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114
20. Kamb A (1995) Cell-cycle regulators and cancer. Trends Genet 11: 136-140
21. Kamb A, Gruis NA, Weaver Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
22. Koh J, Enders GH, Dynlacht BD and Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510
23. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358: 15-16
24. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL and Fodstad O (1996) Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-916
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1: 686-692
26. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB and Andrulis IL (1995) Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4: 1089-1092
27. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clearly K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vollstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
28. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
29. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH and Harris CC (1994a) Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049
30. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Greenblatt MS, Serrano M, Shibeka M, Yokota J, Beach DH and Harris CC (1994b) p16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harb Symp Quant Biol 59: 49-57
31. Pines J (1994) Cell cycle. p21 inhibits cyclin shock. Nature 369: 520-521
32. Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J, Preudhomme C and Peyrat JP (1995) Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 72: 351-353
33. Reed JA, Loganzo Jr F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW and Albino AP (1995) Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55: 2713-2718
34. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633
35. Remmele W and Stegner HE (1987) Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8: 138-140
36. Rosen PP and Oberman HA (1992) Tumors of the Mammary Gland. AFIP: Washington DC
37. Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
38. Sherr CJ (1994) GI phase progression: cycling on cue. Cell 79: 551-555
39. Sinn HP, Haag D, Ehemann V, Magener A, Goerttler K, Bastert G and Otto HF (1997) DNA-Zytometrie beim Mammakarzinom. Übersicht zur Methodik und zum Stellenwert bei der Prognoseabschätzung. Pathologe 18: 19-26
40. Tam SW, Shay JW and Pagano M (1994) Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 54: 5816-5820
41. UICC (1992) TNM Classification of Malignant Tumours. 4th edn. Springer-Verlag: Berlin
42. Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H and Galle PR (1994) p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9: 195-204
43. Xu L, Sgroi D, Sterner CJ, Beunchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF and Ramesh V (1994) Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res 54: 5262-5264